Systemic and Pulmonary Hemodynamic Tolerability of Escalating Intravenous Epoprostenol Infusion in Isoflurane-Anesthetized Healthy Dogs

Continuous intravenous epoprostenol (prostacyclin, PGI2) is a cornerstone therapy for severe human pulmonary arterial hypertension, yet its hemodynamic safety profile in dogs remains incompletely defined. This study evaluated the systemic and pulmonary hemodynamic responses and acute tolerability of continuous intravenous epoprostenol titration in healthy, isoflurane-anesthetized dogs as a prerequisite for future pulmonary hypertension trials. Eight healthy beagle dogs were instrumented for invasive arterial and pulmonary arterial monitoring and received sequential escalating epoprostenol infusions at 1, 5, 10, 15, and 20 ng/kg/min (Epo1–Epo20; 30 min per step), followed by a 20 min washout period. All dogs completed the protocol without major complications. Systemic arterial pressures decreased in a dose-dependent manner, reaching statistical significance only at Epo20 (p < 0.05), without inducing clinically overt hypotension (mean arterial pressure < 60 mmHg). Cardiac output was preserved throughout, supported by a non-significant numerical increase in stroke volume (up to 25%) alongside a numerical reduction in systemic vascular resistance (up to 28%) and unchanged heart rate. Pulmonary arterial pressures, pulmonary vascular resistance, and oxygen delivery remained unchanged, whereas hemoglobin decreased modestly at Epo15 and Epo20 (p < 0.05). In conclusion, intravenous epoprostenol up to 20 ng/kg/min was systemically tolerated without overt hypotension, although pulmonary vasodilatory efficacy requires evaluation in dogs with pulmonary hypertension.

Authors

Institutions

Publication Details

Journal
Animals
Published
2026-11-19
DOI
https://doi.org/10.3390/ani16223679
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Systemic and Pulmonary Hemodynamic Tolerability of Escalating Intravenous Epoprostenol Infusion in Isoflurane-Anesthetized Healthy Dogs

Kazumi Shimada, Ryou Tanaka, Ahmed A. Gh. Farag, Tomohiko Yoshida et al.
Animals
Pulmonary Hypertension Research and Treatments
article

Systemic and Pulmonary Hemodynamic Tolerability of Escalating Intravenous Epoprostenol Infusion in Isoflurane-Anesthetized Healthy Dogs

Kazumi Shimada, Ryou Tanaka, Ahmed A. Gh. Farag, Tomohiko Yoshida, Shigeharu Semba
article en

Abstract

Continuous intravenous epoprostenol (prostacyclin, PGI2) is a cornerstone therapy for severe human pulmonary arterial hypertension, yet its hemodynamic safety profile in dogs remains incompletely defined. This study evaluated the systemic and pulmonary hemodynamic responses and acute tolerability of continuous intravenous epoprostenol titration in healthy, isoflurane-anesthetized dogs as a prerequisite for future pulmonary hypertension trials. Eight healthy beagle dogs were instrumented for invasive arterial and pulmonary arterial monitoring and received sequential escalating epoprostenol infusions at 1, 5, 10, 15, and 20 ng/kg/min (Epo1–Epo20; 30 min per step), followed by a 20 min washout period. All dogs completed the protocol without major complications. Systemic arterial pressures decreased in a dose-dependent manner, reaching statistical significance only at Epo20 (p < 0.05), without inducing clinically overt hypotension (mean arterial pressure < 60 mmHg). Cardiac output was preserved throughout, supported by a non-significant numerical increase in stroke volume (up to 25%) alongside a numerical reduction in systemic vascular resistance (up to 28%) and unchanged heart rate. Pulmonary arterial pressures, pulmonary vascular resistance, and oxygen delivery remained unchanged, whereas hemoglobin decreased modestly at Epo15 and Epo20 (p < 0.05). In conclusion, intravenous epoprostenol up to 20 ng/kg/min was systemically tolerated without overt hypotension, although pulmonary vasodilatory efficacy requires evaluation in dogs with pulmonary hypertension.

AnimalsVol. 16(22)
Zagazig University (EG), Tokyo University of Agriculture and Technology (JP)
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon